Clinical Trials Logo

Heart Diseases clinical trials

View clinical trials related to Heart Diseases.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06468787 Completed - GYN Disorders Clinical Trials

Kosmos Anatomical Object Labeling and View Identification Pivotal Study

Start date: February 7, 2024
Phase: N/A
Study type: Interventional

This is a multi-site, multi-group study that obtained two sets of ultrasound scans from all enrolled participants. Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is computed.

NCT ID: NCT06464354 Completed - Clinical trials for Ischemic Heart Disease

Comparison of the Mammary Harvesting Technique

Start date: June 1, 2023
Phase:
Study type: Observational

The skeletonization technique of left internal artery (LIMA) harvesting is reported as more spar-ing to the vascular supply of the sternum. Some studies report a greater length and greater flow of the graft additionally. The aim of our study was to measure the difference in post-op sternal blood supply compared to the pedicle harvesting technique and to measure the length and flow of the LIMA graft.

NCT ID: NCT06401460 Completed - Clinical trials for Coronary Heart Disease

Yannianjiuzhuan Method and Reverse Breathing Training to Improve Constipation in Elderly Patients With Coronary Heart Disease

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Primary Purpose: The primary purpose of this study is to evaluate the effectiveness of the Yannianjiuzhuan method combined with reverse abdominal breathing in improving symptoms of constipation, anxiety, sleep quality, and overall quality of life in elderly patients with coronary heart disease and constipation. Study Phase: As this research involves a non-pharmacological intervention, it is categorized as Not Applicable (N/A). Intervention Model: Parallel Assignment. Patients are divided into two groups; one receives standard care, while the other receives standard care supplemented by the Yannianjiuzhuan method combined with reverse abdominal breathing. Number of Arms: Two arms are involved in the study. One arm serves as the control group receiving standard care, and the other as the experimental group receiving standard care plus the Yannianjiuzhuan method combined with reverse abdominal breathing. Masking: This study employed a double-blind (assessors and statisticians), randomized, parallel-controlled trial design to enhance the credibility of the results and to minimize bias. Allocation: Using simple random sampling, small folded papers marked with the numbers "1" and "2" were placed in an opaque box. Each patient drew a paper in sequence of enrollment; those drawing a "1" were assigned to the control group, and those drawing a "2" to the experimental group, with each group comprising 35 participants. Enrollment: A total of 70 patients were initially recruited, with 67 completing the study. The control group had one participant drop out due to early hospital discharge related to the pandemic, affecting data collection completeness. In the experimental group, one participant was excluded due to undergoing colonoscopy and taking related laxative medications during the treatment, and another due to early hospital discharge caused by the pandemic. Thus, data from three participants were excluded from the final analysis due to insufficient treatment duration (less than two-thirds of the planned intervention), resulting in 34 participants in the control group and 33 in the experimental group being analyzed, equating to a dropout rate of approximately 4.3%, which is within acceptable statistical limits. Study Classification: This study focuses on efficacy assessment. It particularly evaluates the effectiveness of the Yannianjiuzhuan method combined with reverse abdominal breathing in alleviating symptoms of constipation, anxiety, improving sleep quality, and enhancing the quality of life among elderly patients with coronary heart disease and constipation.

NCT ID: NCT06392243 Completed - Heart Diseases Clinical Trials

IntraCardiac Echocardiography sysTem

DISTINCT
Start date: October 22, 2022
Phase: N/A
Study type: Interventional

To evaluate the safety and effectiveness of intracardiac ultrasound imaging system in Sonosemi Medical Co., Ltd.

NCT ID: NCT06386458 Completed - Atrial Fibrillation Clinical Trials

Assessing AThrough Radiofrequency Transseptal Puncture System for Left Atrial Access

Start date: July 8, 2022
Phase: N/A
Study type: Interventional

This study is a prospective, multicenter, randomized controlled trial with a non-inferiority design. Participants are patients scheduled for atrial septal puncture. After signing informed consent, subjects will be randomly assigned to either the radiofrequency transseptal puncture system group (referred to as the trial group) or the traditional mechanical transseptal puncture system group (referred to as the control group). All participants will undergo immediate postoperative and discharge clinical follow-ups.

NCT ID: NCT06379503 Completed - Cardiac Disease Clinical Trials

Effect of Heart Yoga Applıed To Patıents Undergoıng Cardıovascular Surgery on Sleep, Depressıon And Qualıty of Lıfe

Start date: December 15, 2021
Phase: N/A
Study type: Interventional

This type of study is a randomized controlled trial. The aim is to contribute to the literature by comparing the effects of heart yoga on the depression level, sleep and quality of life of patients who do and do not do heart yoga. The main elements it aims to answer are: - Heart yoga applied to patients who have undergone heart surgery improves their sleep quality compared to those who have not. - Heart yoga applied to patients who have undergone heart surgery reduces the level of depression compared to those who have not. - Heart yoga applied to patients who have undergone heart surgery increases the quality of life compared to those who have not. Patients who accept the study will practice heart yoga simultaneously with heart yoga videos via an online link every other day for 12 weeks after heart surgery. Researchers will compare intervention and control groups to see if there are any effects on sleep quality, depression level, and quality of life.

NCT ID: NCT06347510 Completed - Clinical trials for Congestive Heart Failure

The Level of sST2 in Pediatric Heart Failure

Start date: August 16, 2021
Phase:
Study type: Observational [Patient Registry]

Introduction: Suppression of tumorigenicity 2 (ST2) is a receptor member belongs to the Interleukin-1 (IL-1) family. The ligand and soluble versions are its two isoforms. The interleukin-33-ST2 ligand complexs development provides protection against heart fibrosis and hypertrophy. Investigations on heart failure in adults has demonstrated that it does not change by age, body mass index (BMI), creatinine, hemoglobin, and albumin levels, in contrast to NT pro brain natriuretric peptit. In adult heart failure patients, it has been demonstrated to be an independent predictor of mortality and cardiovascular events. The most recent guideline recommends using it as class 2b in the diagnosis of adult heart failure. Studies on ST2 in children are rare. The purpose of this study is to assess the prognostic value of ST2 for cardiovascular events in young individuals suffering from heart failure. Method: The study included pediatric patients (0-18 years old) with congenital heart disease or cardiomyopathy who needed medical care as well as surgical or interventional treatment. Height, weight, gender, saturation, heart failure classification (Ross or New York heart Assosiation), medications taken, the electrocardiogram, echocardiography, Pro BNP, and sST2 values of the patients, as well as any hospitalization, lower respiratory tract infection, organ dysfunction, or need for angiography or surgery during follow-up Data on arrhythmia and death were gathered during a 1-year follow-up. The SPSS software application was used to carry out the statistical analysis.

NCT ID: NCT06335901 Completed - Clinical trials for Coronary Heart Disease

Clinical Characteristics and Outcomes of Coronary Heart Disease

IMPROVE
Start date: February 1, 2020
Phase:
Study type: Observational

This study evaluated and compared the prognostic value of different Baseline data and clinical variables to develop a risk ractor ediction model in patients with CHD.

NCT ID: NCT06295575 Completed - Clinical trials for Congenital Heart Disease

Effect of Probiotics on Patients With Congenital Heart Disease Following Cardiopulmonary Bypass

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

A randomized, controlled study including infants with non-cyanosis congenital heart disease (CHD) in need of surgical correction involving cardiopulmonary bypass (CPB) was established. Infants aged 1 month to 1 years were enrolled between June 2021 and July 2022. The patients in treatment group were supplied with probiotics consisting of Bifidobacterium infantis and Lactobacillus perioperatively and patients in control group were provided with placebo. Data concerning patients' clinical outcome such as diarrhea were collected. Blood samples were collected for measurement of fatty acid binding protein 2 (FABP2), diamine oxidase (DAO), d-lactic acid (D-LA) and C-reactive protein (CRP). Stool samples were collected to investigate the changes of intestinal flora.

NCT ID: NCT06292910 Completed - Clinical trials for Congenital Heart Disease

Central Venous to Arterial CO2 Difference and Low Cardiac Output Syndrome Related Outcomes in Children After Cardiac Surgery

VACO2
Start date: August 8, 2021
Phase:
Study type: Observational

The goal of this clinical trial is to compare the capability of 3 different bedside surrogates in children who underwent cardiac surgery and were admitted in intensive care unit. These test are lactate, oxygen saturation from central venous and the carbon dioxide gap between central venous and arterial. The main questions is which one is the best prognostication for post operation poor outcomes Participants will be taken routine blood test for post cardiac care (at ICU arrival, 6, 12, and 24 hour post operation) and follow the their outcomes. There is no any intervention or drug in this research